Cambridge Investment Research Advisors Inc. Lowers Holdings in Danaher Corporation (NYSE:DHR)

Cambridge Investment Research Advisors Inc. reduced its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 8.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,510 shares of the conglomerate's stock after selling 4,204 shares during the quarter. Cambridge Investment Research Advisors Inc.'s holdings in Danaher were worth $9,330,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Heck Capital Advisors LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $27,000. Rialto Wealth Management LLC bought a new stake in shares of Danaher in the 4th quarter valued at about $34,000. Hurley Capital LLC purchased a new stake in shares of Danaher in the 4th quarter worth approximately $34,000. Dunhill Financial LLC boosted its stake in shares of Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares in the last quarter. Finally, Ameriflex Group Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $38,000. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DHR. Citigroup restated a "buy" rating on shares of Danaher in a report on Monday, April 7th. TD Cowen upped their price objective on Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Evercore ISI dropped their price objective on Danaher from $240.00 to $230.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 22nd. Robert W. Baird reduced their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Finally, UBS Group decreased their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Trading Up 1.7%

Shares of NYSE:DHR opened at $200.85 on Thursday. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The stock has a market cap of $143.74 billion, a price-to-earnings ratio of 39.00, a PEG ratio of 2.77 and a beta of 0.77. The business has a 50-day moving average price of $194.31 and a 200-day moving average price of $209.00.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.64%. Danaher's dividend payout ratio (DPR) is 24.85%.

Insider Activity at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.